U.S. flag An official website of the United States government
  1. Home
  2. Advisory Committees
  3. Committees and Meeting Materials
  4. Blood, Vaccines and Other Biologics
  5. Vaccines and Related Biological Products Advisory Committee
  6. January 14, 2016: Vaccines and Related Biological Products Advisory Committee Meeting Draft Agenda
  1. Vaccines and Related Biological Products Advisory Committee

January 14, 2016: Vaccines and Related Biological Products Advisory Committee Meeting Draft Agenda

Food and Drug Administration
Center for Biologics Evaluation and Research (CBER)

January 14, 2016

141st Vaccines and Related Biological Products Advisory Committee Meeting
Via Teleconference

Office of Vaccines Research and Review (OVRR)
Division of Viral Products (DVP)
Laboratory of Method Development (LMD)
Building 31, Great Room, Salon A
Silver Spring, MD

Live Webcast: https://collaboration.fda.gov/vrbpacsem1/

Draft Agenda
Time Presentation/Presenter
  Open Session
1:00 p.m. Call to Order and Opening Remarks
Robert Daum, M.D., Chair
  Conflicts of Interest Statement
Sujata Vijh, Ph.D., DFO
  Topic: Presentations of the Laboratory of Method Development, Division of Viral Products, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research
1:15 p.m. Overview of CBER Research/Site Visit Process
Carolyn Wilson, Ph.D.
Associate Director for Research
CBER, FDA
1:35 p.m. Overview of OVRR
Konstantin Chumakov, Ph.D.
Associate Director for Research
OVRR, CBER, FDA
1:50 p.m. Overview of DVP
Jerry Weir, Ph.D.
Director
DVP, CBER, FDA
2:00 p.m. Overview of LMD
Steven Rubin, Ph.D.
Acting Laboratory Chief
LMD, DVP, CBER, FDA
2:30 p.m. Questions
2:35 p.m. Open Public Hearing (if no speakers, will move directly to closed session)
3:35 p.m. Closed Session
5:00 p.m. Adjournment